NSI-189 vs RG3 (Rhodiola)

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

NSI-189 and RG3 (Rhodiola) are both cognitive enhancement peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares NSI-189 and RG3 (Rhodiola) across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

NSI-189RG3 (Rhodiola)
CategoryCognitive EnhancementCognitive Enhancement
Regulatory status (US)Research use onlyResearch use only
Typical dosageResearch protocols vary3-6 mg
Frequencyresearchdaily
Reported benefitsHippocampal growth, potential depression treatment, cognitive enhancementStress reduction, cognitive enhancement, energy
Reported side effectsExperimental. Side effects under investigationWell-tolerated

Key differences

Primary use. NSI-189 is categorised under Cognitive Enhancement, while RG3 (Rhodiola) falls under Cognitive Enhancement. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. NSI-189: not FDA-approved; treated as a research compound. RG3 (Rhodiola): not FDA-approved; treated as a research compound.

Dosing. NSI-189 is typically dosed at Research protocols vary (research). RG3 (Rhodiola) is typically dosed at 3-6 mg (daily).

Can you stack them?

Some protocols combine peptides, but stacking NSI-189 and RG3 (Rhodiola) has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between NSI-189 and RG3 (Rhodiola)?
NSI-189 and RG3 (Rhodiola) are both cognitive enhancement peptides, but they differ in mechanism, dosing, and regulatory status. NSI-189 is not FDA-approved; generally classified as a research compound, whereas RG3 (Rhodiola) is not FDA-approved; generally classified as a research compound.
What is NSI-189 used for?
Neurogenesis, depression.
What is RG3 (Rhodiola) used for?
Adaptogenic peptide.
Can you take NSI-189 and RG3 (Rhodiola) together?
Some users combine peptides within a single protocol, but stacking NSI-189 and RG3 (Rhodiola) has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is NSI-189 or RG3 (Rhodiola) FDA-approved?
NSI-189 is not FDA-approved; generally classified as a research compound. RG3 (Rhodiola) is not FDA-approved; generally classified as a research compound.

Read the full articles

  • NSI-189 — full monograph: mechanism, research, dosing & references
  • RG3 (Rhodiola) — full monograph: mechanism, research, dosing & references

More Cognitive Enhancement comparisons

← All peptide comparisons